68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

Not Applicable

Completed

• Conditions: 68Ga-PSMA HBED-PET/CT; Prostate Cancer
• Interventions: Drug: 68Ga- PSMA

• Registration Number: NCT02920229
• Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Brief Summary

Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional morphological and functional imaging (transrectal ultrasound, bone scan, 18F-FMC PET/CT, CT/MRI) or doubtful imaging of 2-deoxy-2-\[fluorine-18\] (18F)-fluoromethylcholine (FMC) PET/CT will receive a Gallio-68 (68Ga)- Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) scan.

Detailed Description

Single-center, prospective, diagnostic trial. The primary objective of this study is to evaluate the sensitivity of 68Ga-PSMA PET /CT defined as the ratio between the number of 68Ga-PSMA PET /CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging.

The secondary objectives are:

* Sensitivity for different Prostatic Specific Antigen (PSA) values (ranges)

* Sensitivity for different lesion sites

* Treatment response assessment with a second PET

* False positives detection during Follow Up (FUP) (with other standard methods and eventually optional biopsy) for patient without any treatment

* safety 67 evaluable patients will be injected with 100-200 megabecquerel (MBq) 68Ga-PSMA intravenously

Study Timeline

• Study Start: 2015-11
• Study First Submitted: 2016-04-11
• Study First Submitted QC: 2016-09-29
• Study First Posted: 2016-09-30
• Primary Completion: 2020-10-09
• Study Completion: 2020-10-09
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-08
• Last Update Posted: 2025-01-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 1230

Inclusion Criteria

1. Patients must have histologically or cytologically confirmed prostate cancer
2. Male, aged >18 years.
3. Radical treatment for prostate cancer (radiotherapy or surgery)
4. 18F-FMC PET/CT negative or doubtful
5. Negativity of all the other traditional morphological and functional imaging (transrectal ultrasound, bone scan, CT/MRI)
6. Patients with PSA progression defined as PSA ≥ 1,0 ng/mL and/or PSA rising defined as 2 subsequent values showing PSA increase at least 1 week apart.
7. Male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter
8. Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria

1. No hormonotherapy in the last 6 months
2. No radiotherapy in the last 6 months.
3. Patients with PSA < 1.0 ng/ml
4. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Study Agent.
6. Medical or psychological conditions that would not permit the subject to complete to sign informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
68Ga- PSMA PET/CT	68Ga- PSMA	100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT

Primary Outcome Measures

Name	Time	Method
the ratio between the number of 68Ga-PSMA PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging	up to 24 months	the ratio between the number of 68Ga-PSMA PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging

Secondary Outcome Measures

Name	Time	Method
Sensitivity for different PSA values (ranges)	up to 24 months	Sensitivity of 68Ga- PSMA PET/CT for different PSA values (ranges)
Sensitivity for different lesion sites	up to 24 months	Sensitivity of 68Ga- PSMA PET/CT for different lesion sites
PSA decrease: the receiver operating characteristic (ROC) curves generated by plotting sensitivity versus 1-specificity. Youden's index will be used for determining cut-off value between pos and neg 68Ga-PSMA PET/CT findings	up to 24 months	for patients that will start an anticancer treatment: evaluate the predictive role of 68Ga- PSMA PET/CT on early response to therapy (hormonotherapy, abiraterone, enzalutamide) taking PSA decrease as a reference.
number of treated patients experiencing grade 1 to 4 adverse events	up to 24 months	number of treated patients undergoing grade 1 to 4 adverse events evaluated according to CTCAE v.4.0
Evaluation of the concordance between 68Ga- PSMA PET/CT and PET/CT or the others standard methods, performed by the Cohen's kappa coefficient.	up to 24 months	for patient without any treatment: evaluate the concordance between 68Ga- PSMA PET/CT and other standard methods and eventually optional biopsy
percentage of treated patients experiencing grade 1 to 4 adverse events	up to 24 months	percentage of treated patients experiencing grade 1 to 4 adverse events

Trial Locations

Locations (1)

Irst Irccs; 🇮🇹 Meldola, FC, Italy